BEGIN:VCALENDAR
VERSION:2.0
PRODID:-// - ECPv5.9.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://cvg.ca
X-WR-CALDESC:Events for 
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20210101T000000
END:STANDARD
TZID:Asia/Karachi
BEGIN:STANDARD
TZOFFSETFROM:+0500
TZOFFSETTO:+0500
TZNAME:PKT
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20220929T173000
DTEND;TZID=UTC:20220929T183000
DTSTAMP:20260511T001839
CREATED:20220828T132632Z
LAST-MODIFIED:20220828T133140Z
UID:718-1664472600-1664476200@cvg.ca
SUMMARY:CVG 2022 Seminar-8: Mindfulness:  can it change the brain? 
DESCRIPTION:Speaker: Dr. Liz Pang \n\n\n\n Seminar will be conducted online via Zoom @ 5:30 pm EDT \n\n\n\nAbstract\n\n\n\nMindfulness is a concept that has been receiving a lot of attention in our popular culture.  As a basic concept\, it is defined as having a moment-by-moment awareness of what is happening in one’s own self and in one’s surroundings while holding an open and non-judgemental attitude.  Cultivated primarily by the practice of mindfulness meditation\, mindfulness has claimed to offer a list of mental and physical health benefits.  The advent of modern brain imaging has allowed these claims to be tested and there is now substantial evidence that a practice of mindfulness meditation can change the brain in beneficial ways.  This talk will present some of this research\, demonstrate some mindfulness practices\, and discuss some of the benefits from a neuroscience perspective. \n\n\n\n\n\nAbout Speaker \n\n\n\n\n\n\n\nDr. Liz Pang\, Ph.D. is a neurophysiologist and Senior Associate Scientist at the Hospital for Sick Children.  Dr. Pang’s research programme uses brain imaging techniques to examine the development of cognitive brain function in typically developing children and in children who do not develop typically.  Dr. Pang has published 120+ research articles in journals including Nature Neuroscience\, Developmental Cognitive Neuroscience and Human Brain Mapping\, and she has presented her work at conferences around the world.  In her personal pursuit of mental wellness\, Dr. Pang experienced the benefits of mindfulness meditation and was motivated to understand the neuroscience that underpins a mindfulness practice.  Impressed by the evidence\, Dr. Pang now teaches a course on the Neuroscience of Mindfulness and Mindfulness Meditation at the University of Toronto School of Continuing Studies.   \n\n\n\nShe can be reached at elizabeth.pang@utoronto.ca 
URL:https://cvg.ca/event/cvg-2022-seminar-8/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220824T173000
DTEND;TZID=UTC:20220824T183000
DTSTAMP:20260511T001839
CREATED:20220813T150616Z
LAST-MODIFIED:20220828T133034Z
UID:699-1661362200-1661365800@cvg.ca
SUMMARY:CVG 2022 Seminar-7: Stability Study for Pharmaceuticals
DESCRIPTION:Speaker: Dr. Chung Chow Chan  \n\n\n\n Seminar will be conducted online via Zoom @ 5:30 pm EDT \n\n\n\nAbstract\n\n\n\nThe purpose of stability testing in the pharmaceutical industry is to understand how the quality of a drug substance or drug product varies with time under the influence of a variety of environmental factors such as temperature\, humidity\, and light.  The data that are collected from the stability studies will help to establish a re-test period for the drug substance or a shelf life for the drug product and recommended storage conditions.  This presentation will provide an overview of development and formal stability studies that will be used during the development of a drug product. \n\n\n\n\n\n\n\n\n\n\n\n\n\nAbout Speaker \n\n\n\n\n\n\n\nDr. Chung Chow Chan is an expert in development of GxP quality programs and analytical method development/validation. In addition to his role at Covar\, he is a member of the Prescription/Non-Prescription Stakeholders and General Chapters Project Teams for the United States Pharmacopeia.  \n\n\n\nDr. Chan was Senior Director of Project/Program Management and Analytical Services at Azopharma\, where he led validation strategies and Phase I development programs. Before Azopharma\, Dr. Chan was a Technical Manager and Principal Research Scientist at Eli Lilly\, where he led early/late development projects\, method validations\, and IND/NDA submissions. Dr. Chan also worked at Glaxo as a Research Scientist and Manager.  \n\n\n\nDr. Chan received his B.Pharm. (Hons) from the University Sains Malaysia\, Malaysia\, M.S. in Medicinal Chemistry from Dalhousie University\, Canada\, and Ph.D. in Medical and Analytical Chemistry from Purdue University\, Indiana. He is also the author and editor of three books\, most recently “Therapeutic Delivery Solutions” (John Wiley & Sons\, 2014)\, and is a Registered Pharmacist in Ontario\, Canada.
URL:https://cvg.ca/event/cvg-2022-seminar-7/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220721T173000
DTEND;TZID=UTC:20220721T183000
DTSTAMP:20260511T001839
CREATED:20220713T010416Z
LAST-MODIFIED:20220713T011135Z
UID:679-1658424600-1658428200@cvg.ca
SUMMARY:CVG 2022 Seminar-6: X-ray Crystallography for Pharmaceuticals  
DESCRIPTION:Speaker: Dr. Jim Britten and Vicky Jarvis  \n\n\n\n Seminar will be conducted online via Zoom @ 5:30 pm EDT \n\n\n\nAbstract\n\n\n\nIn this presentation we will take a quick look at the process of X-ray diffraction from crystalline materials. We will demonstrate the process of determining the structure and absolute configuration of an organic molecule using single crystal analysis. We will use powder diffraction for phase ID\, polymorph differentiation\, stability studies\, and impurity detection. We will illustrate different sample forms that can be used for 2D diffraction experiments. Finally\, we look at X-ray scattering from amorphous phases.  \n\n\n\n\n\nAbout Speaker \n\n\n\n\n\n\n\nJim Britten received his PhD from McMaster University in 1984. After an NSERC postdoc at the Université de Montréal and a Killam postdoc at Dalhousie University\, he became the crystallographer for the McGill Chemistry Department. In 1991 he became the Manager of the McMaster X-ray Facility\, Jim has served as the Chair of the Canadian National Committee for Crystallography and as a member of Council for the American Crystallographic Association (ACA). He is a Fellow of the ACA. He was Chair of the Program Committee for the 2014 International Union of Crystallography Congress in Montreal. He and Vicky Jarvis originated the Canadian Chemical Crystallography Workshop and the Canadian Materials Diffraction Workshop\, and he teaches at these and the Canadian Powder Diffraction Workshop each year. He is also a co-author of the MAX3D program for the visualization of 3D diffraction patterns.
URL:https://cvg.ca/event/cvg-2022-seminar-6/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220629T173000
DTEND;TZID=UTC:20220629T183000
DTSTAMP:20260511T001839
CREATED:20220529T140300Z
LAST-MODIFIED:20220531T212156Z
UID:664-1656523800-1656527400@cvg.ca
SUMMARY:CVG 2022 Seminar-5: Ion Chromatography in Pharmaceutical Industry 
DESCRIPTION:Speaker: Dr. PARVIZ SHAHBAZIKHAH \n\n\n\n Seminar will be conducted online via Zoom @ 5:30 pm EDT \n\n\n\nAbstract\n\n\n\nIon chromatography (IC) is the method of choice to determine active ingredients\, excipients\, and traces of impurities\, as well as metabolites in the form of organic and inorganic ions or polar substances\, in a number of pharmaceuticals\, pharmaceutical solutions\, and even body fluids. It can determine the presence of several substances within a very short time in a single analysis – and even distinguish chemically similar analytes. The concentration of analytes can vary from ng/L up to the per cent range. The large selection of separation columns and elution systems available makes IC useful for almost any kind of analyte. Interfering effects caused by the sample matrix can easily be avoided by using the right sample preparation or choosing a suitable detection method. Inline sample preparation is a feature of many modern IC systems\, as the focus of recent advances in IC has been mainly on ease of use. However\, convenience is not the only advantage brought by the automation of the IC process: reducing human interference to a minimum also means reducing the chances of mistakes and contamination.  Depending on the requirements of analyte and matrix\, there is a broad range of detection methods to choose from: Conductivity detection with and without suppression\, Electrochemical detection\, Spectrophotometric detection with and without post-column derivatization (ultraviolet–visible spectrophotometry)\, Coupled detection methods such as IC–mass-spectrometry (MS) and IC–inductively-coupled-plasma-MS.  \n\n\n\n\n\nAbout Speaker \n\n\n\n\n\n\n\nDr. Shahbazikhah has received his PhD in Analytical Chemistry and Chemometrics from Sharif University of Technology in 2008. He finished his postdoc research in collaboration with Prof. John Kalivas at Idaho State University. Dr. Shahbazikhah has extensive experience in Academia and Industry. In his academic experience he has published more than 15 peer review papers in chemometrics and data analysis. Dr. Shahbazikhah also has 20 years hands-on experience in Ion Chromatography\, Electrochemistry\, Titration and Spectroscopy applications in different industries.   
URL:https://cvg.ca/event/cvg-2022-seminar-5/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220420T173000
DTEND;TZID=UTC:20220420T183000
DTSTAMP:20260511T001839
CREATED:20220406T023823Z
LAST-MODIFIED:20220406T023823Z
UID:633-1650475800-1650479400@cvg.ca
SUMMARY:CVG 2022 Seminar-4:Neuroprotection\, Total Brain Health\, and the role of Psychedelics and novel compounds as potential therapeutics"
DESCRIPTION:Speaker: Dr. Lakshmi P. Kotra \n\n\n\n Seminar will be conducted online via Zoom @ 5:30 pm EDT \n\n\n\nAbstract\n\n\n\nThis presentation will discuss how to formulate an oral drug product following a Quality-by-Treatment of neurodegenerative and mental health disorders are a challenge due to the complexities associated with quick diagnosis. Once diagnosed\, available therapies are very limited\, if any\, due to the lack of understanding of associated drug targets. Recent clinical data are also unravelling a close relationship between neurodegenerative disorders and mental health. Total Brain Health™ deals with the health of brain and mind\, addressing neurodegenerative and mental health disorders. We have been working on a novel group of molecules\, and the role of psychoactive compounds to potentially address Total Brain Health targeting neurodegenerative disorders and mental health disorders. This presentation will focus on drug discovery and development in pursuit of novel treatments for multiple sclerosis and major depression disorder.    \n\n\n\n\n\nAbout Speaker \n\n\n\n\n\n\n\nDr. Lakshmi Kotra is a Professor of Medicinal Chemistry at the University of Toronto and a Senior Scientist at Krembil Brain Institute\, University Health Network (UHN). He also leads Lucid Psycheceuticals\, a subsidiary of FSD Pharma\, its operations and strategy as CEO.  \n\n\n\nDr. Kotra brings a wealth of experience from discovery to advanced stages of drug development\, building products and business based on fundamentals and pragmatism. Dr. Kotra is an inventor of multiple technologies and holds several patents. He has authored/co-authored over 130 publications and delivered over 140 scientific talks internationally.  \n\n\n\nDr. Kotra is the recipient of several recognitions and awards over the years\, including the Julia Levy Award from the Society of Chemical Industry (SCI) Canada in 2021 in recognition of his substantial contribution to the successful commercialization of innovation in Canada in the field of biomedical science and engineering. Dr. Kotra has led or participated in a number of important drug discovery and development projects\, including anti-HIV drugs\, antibacterials\, insulin\, antimalarials\, medical cannabis-based therapeutics\, and drugs targeting multiple sclerosis (MS). In addition to Lucid Psycheceuticals\, he co-founded WinSanTor Biosciences\, a San Diego\, CA-based company developing treatments for peripheral neuropathies\, and CannScience Innovations (Scientus Pharma)\, a Toronto\, ON-based company focused on medical cannabis and cannabinoids. Dr. Kotra received B.Pharm.(Hons) from Birla Institute of Technology & Science (India)\, Ph.D. in Pharmacy (Medicinal Chemistry) from the University of Georgia\, and completed postdoctoral training at Wayne State University.
URL:https://cvg.ca/event/cvg-2022-seminar-4/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220323T173000
DTEND;TZID=UTC:20220323T183000
DTSTAMP:20260511T001839
CREATED:20220309T171651Z
LAST-MODIFIED:20220309T171743Z
UID:618-1648056600-1648060200@cvg.ca
SUMMARY:CVG 2022 Seminar-3:Quality-by-Design Approaches to Develop a Robust Oral Formulation
DESCRIPTION:Speaker: Dr. Kwok Chow \n\n\n\n Seminar will be conducted online via Zoom @ 5:30 pm EDT \n\n\n\nAbstract\n\n\n\nThis presentation will discuss how to formulate an oral drug product following a Quality-by-Design approach.  Mechanistic and risk assessment strategies to evaluate and characterize drug substance for product development will be provided. The use of a decision tree based on API properties for dosage form design will also be discussed. Topics and examples related to effective use of statistical design of experiment and target product profile will also be included in the presentation.     \n\n\n\n\n\nAbout Speaker \n\n\n\n\n\n\n\nDr. Kwok Chow is an expert in product development and drug delivery systems. Currently\, he is the President of Covar Pharmaceuticals Inc. and Power Pharma Coating Inc. He has served as a Scientific Advisor to the Editors of the Journal of Pharmaceutical Sciences and a core member of the Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology at Health Canada. \n\n\n\nDr. Chow was the Senior Director of Global PDS Technology and Alliances at Patheon Inc. with the responsibility of introducing new technologies\, establishing strategic alliances and supporting the development of challenging molecules. Before this Dr. Chow was Director of Formulation Development\, responsible for all formulation development activities in Patheon\, Canada\, and specializing in a wide range of products including tablets\, soft gelatin capsules\, liquids\, topicals\, suspensions\, nasal sprays\, powder for reconstitution\, combination and fast dissolving formulations\, etc. Dr. Chow also developed a screening program (SoluPath) to improve bioavailability of poorly soluble drugs. \n\n\n\nDr. Chow began his career at Glaxo where he led the development of new chemical entities and line extension products for North American\, European\, Japan and Asia Pacific markets. Dr. Chow received his B.S. in Pharmacy from the University of Minnesota and his Ph.D. in Industrial Pharmacy from Professor David Grant at the University of Toronto. Dr. Chow also serves as an Adjunct Professor at the Chinese University of Hong Kong\, School of Pharmacy.
URL:https://cvg.ca/event/cvg-2022-seminar-3/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220224T173000
DTEND;TZID=UTC:20220224T183000
DTSTAMP:20260511T001839
CREATED:20220122T135815Z
LAST-MODIFIED:20220122T135816Z
UID:592-1645723800-1645727400@cvg.ca
SUMMARY:CVG 2022 Seminar-2:Data Integrity: A Critical Component of the Product Lifecycle
DESCRIPTION:Speaker: Dr. Pauline L. McGregor  \n\n\n\n Seminar will be conducted online via Zoom @ 5:30 pm EDT \n\n\n\nAbstract\n\n\n\nMedicinal products are released to patients based on decisions that claim they are of the required  identity\, purity\, quality\, safety and efficacy for the intended use. These decisions are supported by the generation\, documentation and review of any data associated with the product\, including the source of materials\, the manufacturing process and methods of testing. Data governance\, good data/ record management practices and ensuring the integrity of the data are therefore critical components of a company’s quality system.    \n\n\n\nThis presentation provides an overview of regulatory expectations in a GMP environment for data management programs and presents an insight into data integrity\, data governance\, and good documentation practices for paper and electronic data. Although the focus is on a GMP environment\, the data practices discussed\, are also relevant and can be applied across the product lifecycle. \n\n\n\n\n\nAbout Speaker \n\n\n\n\n\n\n\nPauline holds a PhD in organic\, analytical chemistry and has fulfilled a variety of roles in over thirty years in the pharmaceutical industry.  She founded PMcG Consulting in September 2006.  \n\n\n\nShe is an expert in quality systems and procedures\, GMP regulations and analytical chemistry.   \n\n\n\nShe brings a technical expertise to laboratories and manufacturers which enable her to assist them to develop\, transfer\, verify and validate analytical procedures and manufacturing processes\, and also optimize efficiency with regards to operations and troubleshooting both in development and GMP environments. Pauline also has the experience and ability to customize and install the quality systems required to allow new manufacturing and testing companies to operate to GMP regulations and review and improve on current quality systems to allow more efficient operations.  \n\n\n\nShe is a renowned trainer in her areas of expertise\, a valuable consultant\, and a detailed oriented auditor. She has utilized her skill set globally in the UK\, Canada\, US\, Jordan\, Brazil\, and China and has helped companies prepare for a GMP inspection to gain their European/Health Canada/FDA GMP licenses.  \n\n\n\nPauline has been involved in the development and evolution of lifecycle management for analytical procedures since 2010. She  was a member of the USP expert panel for Validation\, Verification and Transfer of Analytical Procedures and a member of a USP Chemical Medicines expert review committee. She continues to be a USP volunteer Expert Advisor and is a Member of the Royal Society of Chemistry \, UK.  
URL:https://cvg.ca/event/cvg-2022-seminar-2/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220119T173000
DTEND;TZID=UTC:20220119T183000
DTSTAMP:20260511T001839
CREATED:20211229T192405Z
LAST-MODIFIED:20220106T192927Z
UID:558-1642613400-1642617000@cvg.ca
SUMMARY:CVG 2022 Seminar-1:Bioanalytical Testing for Clinical Studies
DESCRIPTION:Speaker: Dr. Henrianna Pang  \n\n\n\n Seminar will be conducted online via Zoom @ 5:30 pm EDT \n\n\n\nAbstract\n\n\n\nBioanalytical methods to be used in preclinical and clinical studies must be validated and bioanalytical parameters established as defined in regulatory guidelines.  This presentation will describe parameters and validation requirements for quantitative methods based on liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS).  Examples will be used to demonstrate method development and validation does not always stop at quantifying targeted dosed compound in plasma\, biological modification (intended because prodrug is the dosed compound) and degradation products (like glucuronides formation) also required consideration and at times quantification.  \n\n\n\n\n\nAbout Speaker \n\n\n\n\n\n\n\nHenrianna Pang is a pharmaceutical and academic research scientist with in-depth knowledge of mass spectrometry and chromatography.  She has over twenty years of bioanalysis experience in pharmaceutical industry (proprietary and contract research laboratories) ranging from discovery\, GLP preclinical\, and clinical studies.  Specializes in method development\, validation\, high throughput sample analysis and preliminary metabolites identification. She has over ten years of experience in academic research in mass spectrometric applications for wide range of chemical entities.  She holds a Ph.D. in medicinal chemistry from University of Utah and a B.Sc. in chemistry from San Diego State University. 
URL:https://cvg.ca/event/cvg-2022-seminar-1/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20211124T173000
DTEND;TZID=UTC:20211124T183000
DTSTAMP:20260511T001839
CREATED:20211106T213407Z
LAST-MODIFIED:20211106T213830Z
UID:541-1637775000-1637778600@cvg.ca
SUMMARY:CVG 2021 Seminar-4:Clinical Studies and Regulatory Requirements
DESCRIPTION:Speaker: Dr Mary Mazur-Melnyk  \n\n\n\n Seminar will be conducted online via Zoom @ 5:30 pm EDT \n\n\n\nAbstract\n\n\n\nThe presentation will provide an overview of the regulatory process and associated requirements during all phases of clinical study drug development conducted both in the US and Canada with the ultimate focus of market approval.  The main objective is to provide a basic understanding of all the interrelated elements that need to be successfully executed in the drug development process from a regulatory perspective.  Specifically\, the various stages of clinical research; initiation of a clinical trial application its structure and contents and regional differences; overview of essential documents and applicable standards and principles.  \n\n\n\n\n\nAbout Speaker \n\n\n\n Mary Mazur-Melnyk has over 35 years of pharmaceutical and biologics experience specifically in the areas of product development\, scale-up\, quality management\, product management and registration maintenance.  She has established and headed both quality and regulatory teams leading to many successful product registrations at Sanofi Pasteur\, GlaxoWellcome\, Novartis\, Biomira\, Biovail and most recently Ironshore Pharmaceuticals. She holds a Ph.D. in toxicology/molecular biology and a M.Sc. in Medical Sciences. 
URL:https://cvg.ca/event/cvg-2021-seminar-4/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20211027T173000
DTEND;TZID=UTC:20211027T183000
DTSTAMP:20260511T001839
CREATED:20211009T125919Z
LAST-MODIFIED:20211009T130207Z
UID:510-1635355800-1635359400@cvg.ca
SUMMARY:CVG 2021 Seminar-3:Pre-Clinical Toxicology in the Pharmaceutical Industry
DESCRIPTION:Speaker: Dr Robin Walker  \n\n\n\n Seminar will be conducted online via Zoom @ 5:30 pm EDT and 3:30 MDT  \n\n\n\nAbstract\n\n\n\nNon-clinical safety assessment is an essential and important component of the drug development process. It is highly regulated with the main sets of compliance requirements being Good Laboratory Practice (GLP) regulations (OECD and individual country) that stipulate how the data should be collected from a quality perspective and International Conference on Harmonization (ICH)\, OECD\, and individual country regulatory guidelines that specify what types\, designs\, and durations of studies should be conducted. \n\n\n\n\n\nSpeaker: Dr Robin Walker  \n\n\n\n\n\n\n\n\n\n\n\nDr. Robin Walker is an American Board of Toxicology certified toxicologist with over 35 years of experience in nonclinical aspects of drug development. \n\n\n\nAfter obtaining a PhD from the Department of Pathology in collaboration with the Department of Pharmacology and Toxicology at Queen’s University\, Dr. Walker worked for large pharmaceutical companies (Parke-Davis/Warner Lambert and Pfizer) for over 20 years and subsequently as a consultant to private companies and regulatory agencies. \n\n\n\nDr. Walker has extensive experience on international drug development teams with responsibilities for the design\, overall direction\, summarization\, and issue resolution of nonclinical toxicology. He has been a member of highly successful development teams responsible for the development of marketed drugs (Neurontin and Cerebyx) and was responsible for the direction of exploratory and GLP-compliant laboratory operations that supported many other drug development programs. Dr. Walker has been active in the Society of Toxicology of Canada (STC) serving as a councillor on the Board of Directors\, member and chair of the Program Committee\, and member of the Organizing Committee and co-chair of the Program Committee for the International Congress of Toxicology when it was held in Montreal. He also has extensive experience as a study director and monitor of contracted GLP-compliant toxicology studies and has an extensive record of scientific publication. Consulting experience has been with respect to due diligence evaluations\, development of preclinical development plans for small and medium sized pharmaceutical / biotechnology companies\, preparation of CTA/IND/NDS/NDA/MAA and other regulatory documents for new chemical entities and medical devices\, monitoring of toxicology studies at contract laboratories\, and provision of toxicology advice to industry and Health Canada. Dr. Walker has also taught in the Regulatory Affairs Program at Humber College in Toronto and is an adjunct faculty member in the Department of Biomedical and Molecular Sciences at Queen’s University. 
URL:https://cvg.ca/event/cvg-2021-seminar-3/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20210929T173000
DTEND;TZID=UTC:20210929T183000
DTSTAMP:20260511T001839
CREATED:20210908T124814Z
LAST-MODIFIED:20210917T192442Z
UID:471-1632936600-1632940200@cvg.ca
SUMMARY:CVG 2021 Seminar-2:Active Pharmaceutical Ingredient Synthesis
DESCRIPTION:Speaker: Dr John Tobin\, Acanthus Research Inc. \n\n\n\nSeminar will be conducted online via Zoom @ 5:30 pm EDT and 3:30 MDT \n\n\n\nAbstract\n\n\n\nAn overview of the Drug Development Process will be presented based on observations from the perspective of a formulation scientist with 30+ years industry experience. The significance of interdisciplinary collaboration through out all stages of the process (from pre-clinical to post-commercialization) will be discussed. \n\n\n\n\n\nSpeaker: Dr.  John Tobin \n\n\n\n\n\n\n\nDr. John Tobin is the co-founder of Acanthus Research Inc.\, a research-driven organization serving the pharmaceutical industry by providing quality reference standards and synthetic organic chemistry services. \n\n\n\nJohn is a 25-year veteran of the pharmaceutical industry with extensive experience in analytical development for APIs and finished products.  \n\n\n\n \n\n\n\nJohn obtained his Ph.D. in Physical Organic Chemistry from the University of Toronto with research interests in reactive intermediates and enzyme reaction mechanisms. Dr. Tobin’s career has progressed in fields of medicinal chemistry (DuPont Merck Pharmaceuticals)\, diagnostic assay development (Ortho Clinical Diagnostics)\, analytical sciences in pharmaceutical development (GlaxoSmithKline)\, analytical services for a manufacturer of APIs (Torcan Chemicals)\, and analytical projects\, including method development and validation\, stability studies\, and impurity identification\, at a CRO supporting pharmaceutical\, medical device and related industries (Exova). Currently\, Dr. Tobin directs analytical development at Acanthus Research Inc. with focus on analytical certification of new molecules. John enjoys working with synthetic organic chemists addressing the challenges in the manufacture of new chemical entities.
URL:https://cvg.ca/event/cvg-2021-seminar-2/
LOCATION:Online Zoom Meeting\, Canada
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Asia/Karachi:20210901T173000
DTEND;TZID=Asia/Karachi:20210901T183000
DTSTAMP:20260511T001839
CREATED:20210624T223704Z
LAST-MODIFIED:20210830T230507Z
UID:316-1630517400-1630521000@cvg.ca
SUMMARY:CVG 2021 Seminar-1: Overview of the Pharmaceutical Development Process
DESCRIPTION:Speaker: Austin Freeman  \n\n\n\nSeminar will be conducted online via Zoom. \n\n\n\n \n\n\n\nAbstract\n\n\n\nAn overview of the Drug Development Process will be presented based on observations from the perspective of a formulation scientist with 30+ years industry experience. The significance of interdisciplinary collaboration through out all stages of the process (from pre-clinical to post-commercialization) will be discussed. \n\n\n\nSpeaker: Mr. Austin Freeman\n\n\n\nAustin Freedman has extensive and varied experience in Industrial Pharmacy\, Pharmaceutics\, Pharmaceutical R&D and Technology Transfer project leadership in the UK and Canada through Glaxo\, GlaxoWellcome\, GlaxoSmithKline\, Patheon and Apotex. Austin’s accomplishments in technical project leadership are complemented by his skills in business management with P&L accountability\, client relationship management and organizational & operational development.  \n\n\n\n \n\n\n\nAustin earned his Bachelor’s in Pharmacy in 1984 from the University of London\, UK and is a member of the Royal Pharmaceutical Society. His career in the pharmaceutical industry began by joining the Pharmaceutical Research Department of Glaxo Group Research\, UK in 1984.  During the next 15 years\, Austin gained in-depth knowledge and practical understanding in developing a wide range of pharmaceutical solid and liquid (including parenteral) products\, spanning the entire drug development process from pre-clinical development to scale up and transfer to commercial production. In 1999\, Austin transferred to GlaxoWellcome in Ontario\, Canada to contribute his experience to the Pharmaceutical Sciences department\, where he held CMC leadership roles on multi-national project teams developing significant products for GlaxoWellcome and GlaxoSmithKline.  \n\n\n\n  \n\n\n\nSeeking an opportunity to contribute to a rapidly growing organization in a business/client service environment\, Austin joined Formulation Development\, Pharmaceutical Development Services at the Patheon (now Thermo Fisher Scientific) Toronto Region Operations in 2002.  During his 8-year career at Patheon\, Austin had a variety of senior roles that combined his technical knowledge and business leadership to enable multidisciplinary pharmaceutical development units to meet the requirements of diverse portfolios of clients’ projects\, which included formulation and manufacturing process development to support regulatory submissions\, clinical programs and technology transfers.  \n\n\n\n  \n\n\n\nIn 2011\, Austin joined Apotex to lead Technical Operations at the site in Etobicoke\, Ontario\, where he facilitated operational excellence and new product launches in the fast-paced generic pharmaceutical environment. While at Apotex\, Austin developed and implemented technology transfer process improvements to enable manufacturing processes for a wide variety of products to be transferred robustly between sites in Canada\, Europe and India.  \n\n\n\n  \n\n\n\nAustin became an independent consultant in 2015\, and combines his extensive experience in the innovator\, generic and contract sectors of the pharmaceutical industry with his professional training as a pharmacist to provide CMC and Quality Assurance expertise to meet the needs of clients’ projects\, through all stages of development and commercialization. 
URL:https://cvg.ca/event/cvg-2021-seminar-1/
LOCATION:Online Zoom Meeting\, Canada
END:VEVENT
END:VCALENDAR